In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Hold rating on Madrigal Pharmaceuticals (MDGL – Research ...

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Altimmune (ALT – Research Report) yesterday and set a price target of ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

Analyst Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report) and increased the price target to $11.00 from $6.00. Discover outperforming ...

Nektar Therapeutics (NKTR – Research Report) received a Buy rating and a $4.00 price target from B.Riley Financial analyst Mayank Mamtani yesterday. The company’s shares closed yesterday at $1.19.

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on TG Therapeutics (TGTX – Research Report), with a price target of $38.00. The company’s shares ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ironwood Pharma (IRWD – Research Report) and Centessa Pharmaceuticals (CNTA – Research Report).

See the top stocks recommended by analysts >> Nektar Therapeutics (NKTR) B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Nektar Therapeutics today and set a price target of $4.00.

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Cassava Sciences (NASDAQ:SAVA) on Tuesday, setting a price target of $108, which is approximately 55.62% above... Investing.com ...